Belite Bio has completed its NDA submission to the FDA for tinlarebant, a potential first-in-class treatment for Stargardt disease, supported by positive Phase 3 DRAGON trial results.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
Belite Bio has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1). The filing marks an important regulatory milestone for a condition that currently has no approved treatments and affects an estimated 53,000 people in the United States.
The NDA was submitted under the FDA’s Breakthrough Therapy Designation pathway following the initiation of the rolling review process in April 2026. The application will now undergo the agency’s standard 60-day filing review, after which the FDA is expected to determine whether to accept the submission and assign a Prescription Drug User Fee Act (PDUFA) target action date.
Targeting a Key Driver of Retinal Degeneration
STGD1 is a rare inherited retinal disorder caused by mutations in the ABCA4 gene. The disease leads to progressive degeneration of the macula, resulting in irreversible central vision loss that often begins during childhood or early adulthood.
Tinlarebant works by lowering levels of retinol binding protein 4 (RBP4), the sole carrier responsible for transporting vitamin A from the liver to the eye. By reducing retinal exposure to circulating vitamin A, the therapy decreases the formation of toxic vitamin A-derived byproducts known as bisretinoids. These compounds accumulate in retinal cells and are believed to drive disease progression in Stargardt disease.
The mechanism may also have broader relevance in retinal disorders characterized by bisretinoid accumulation, including geographic atrophy, an advanced form of dry age-related macular degeneration.
Phase 3 Data Supported Regulatory Filing
The NDA is supported by results from the Phase 3 DRAGON trial (NCT05244304), which evaluated tinlarebant in patients with STGD1. According to the company, the study met its primary objective, demonstrating a statistically significant reduction in the growth rate of retinal lesions compared with placebo.
Reduction in lesion growth is considered a clinically meaningful structural endpoint because lesion expansion is associated with progressive vision loss. However, the relationship between slowing lesion growth and long-term preservation of visual function continues to be evaluated.
The findings suggest that tinlarebant may slow retinal degeneration in patients with Stargardt disease. The company stated that the therapy demonstrated a favorable benefit-risk profile during development, although detailed safety findings were not included in the announcement.
Regulatory Momentum Builds
The FDA has granted tinlarebant several regulatory incentives, including Breakthrough Therapy Designation, Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in the United States. The therapy has also received Orphan Drug Designation in Europe, Japan, and Switzerland, along with Sakigake Designation in Japan.
Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio, said completion of the NDA submission marks a key step toward bringing the first potential treatment to patients with Stargardt disease, an area with no approved therapeutic options.
Dr. Hendrik Scholl, Chief Medical Officer, highlighted the Phase 3 DRAGON results, noting that tinlarebant significantly reduced retinal lesion growth versus placebo, supporting its potential to become the first approved therapy for the disease.
Regulatory Pathway and Next Steps
The FDA’s acceptance decision is expected following completion of the filing review period. If accepted, the agency will assign a PDUFA date that will define the timeline for a potential approval decision.
Should tinlarebant gain regulatory clearance, it could become the first approved treatment for Stargardt disease and one of only a limited number of approved therapies for inherited retinal disorders, providing a long-awaited therapeutic option for patients facing progressive and irreversible vision loss.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.